Health Care [ 5/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
The company also provides research program for the treatment of Huntington's disease.
In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology.
The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | -0.47 Increased by +11.32% | -0.53 Increased by +11.32% |
| Mar 10, 26 | -0.47 Increased by +20.34% | -0.51 Increased by +7.93% |
| Nov 10, 25 | -0.47 Decreased by -193.75% | -0.52 Increased by +9.62% |
| Aug 6, 25 | -0.57 Decreased by -216.67% | -0.52 Decreased by -9.62% |
| May 6, 25 | -0.53 Decreased by -165.00% | -0.44 Decreased by -20.45% |
| Feb 26, 25 | -0.59 Decreased by -147.20% | -0.35 Decreased by -68.43% |
| Nov 12, 24 | -0.16 Increased by +72.88% | -0.40 Increased by +60.00% |
| Aug 6, 24 | -0.18 Increased by +64.71% | -0.40 Increased by +55.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 2.59 M Decreased by -59.94% | -27.94 M Increased by +9.94% | Decreased by -1.08 K% Decreased by -124.82% |
| Dec 31, 25 | 15.34 M Increased by +144.28% | -27.43 M Increased by +20.47% | Decreased by -178.83% Increased by +67.45% |
| Sep 30, 25 | 13.37 M Decreased by -45.73% | -27.89 M Decreased by -208.40% | Decreased by -208.69% Decreased by -468.33% |
| Jun 30, 25 | 5.20 M Decreased by -82.42% | -33.38 M Decreased by -229.18% | Decreased by -641.96% Decreased by -1.77 K% |
| Mar 31, 25 | 6.47 M Decreased by -66.83% | -31.02 M Decreased by -173.80% | Decreased by -479.24% Decreased by -725.49% |
| Dec 31, 24 | 6.28 M Decreased by -93.03% | -34.49 M Decreased by -161.15% | Decreased by -549.33% Decreased by -977.26% |
| Sep 30, 24 | 24.63 M Increased by +433.79% | -9.04 M Increased by +65.08% | Decreased by -36.72% Increased by +93.46% |
| Jun 30, 24 | 29.58 M Increased by +509.48% | -10.14 M Increased by +54.34% | Decreased by -34.29% Increased by +92.51% |